Taurine is a sulfur-containing amino acid that Ghandforoush-Sattari and colleagues describe as "a normal constituent of the human diet".1 Singh and colleagues call it a semi-essential micronutrient that mammalian cells make from cysteine and can also take up from the diet.2 The app lists taurine as an oral amino acid supplement with a typical dose of 1 to 3 g/day. The app grades the evidence as moderate, which is the app's own grade and not a conclusion of the sources below.

The human studies set out below are one single-dose pharmacokinetic study in eight men, two 12-week randomised trials in specific groups, a meta-analysis of endurance studies with supplementation of up to 2 weeks, and an observational study in men that tests a 2023 aging hypothesis. The lifespan results in the 2023 aging paper are from worms and rodents, and the human trials below do not test lifespan.2

Ghandforoush-Sattari and colleagues write that "Taurine stabilises membranes, modulates calcium transport", and note that about one-fourth of bile acids in the human adult are conjugated with taurine.1 The record of the 2016 psychosis trial describes taurine as "an inhibitory neuromodulatory amino acid in the central nervous system" that "activates the GABA- and glycine-insensitive chloride channel and inhibits the N-methyl-D-aspartate receptor".3 In the blood pressure trial, the authors report that taurine "upregulated the expression of hydrogen sulfide-synthesizing enzymes" and reduced agonist-induced vascular reactivity "through the inhibition of transient receptor potential channel subtype 3-mediated calcium influx in human and mouse mesenteric arteries".4 Those experiments were done in vivo and in vitro, in addition to the 120-person trial.4 In the aging paper, the authors report that taurine "reduced cellular senescence, protected against telomerase deficiency, suppressed mitochondrial dysfunction, decreased DNA damage, and attenuated inflammaging", and the paper reports these mechanisms from its animal and cell experiments, not from a human supplementation trial.2 The app's notes describe GABA-A modulation for sleep continuity; none of the cited sources tests that mechanism in people, and the psychosis trial record names a GABA- and glycine-insensitive channel instead.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
80%
Typical dose
1–3 g/day
Route
Oral
Time to peak
~1 h

The only oral pharmacokinetic study of taurine in healthy people that was identified in PubMed is the 2010 study of Ghandforoush-Sattari and colleagues (Tabriz University of Medical Sciences and Cardiff University), in eight healthy men.1 The second column of the table holds the app's own figures, shown beside what the study reports.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the study
Half-life~1 hPlasma elimination half-life 1.0 ± 0.3 hours, range 0.7 to 1.4 hours, after 4 g by mouth in 8 healthy men1
Time to peak~1 hMean time to maximum concentration 1.5 ± 0.6 hours, range 1 to 2.5 hours; maximum plasma concentration 86.1 ± 19.0 mg/L1
Bioavailability80%The study reports the ratio of clearance to bioavailability (Cl/F) of 21.1 ± 7.8 L/hr and gives no bioavailability percentage1
Volume of distributionNot listed by the appMean 30.0 ± 7.6 L, range 19.8 to 40.7 L1
Return to baselineNot listed by the appPlasma taurine concentrations returned to the normal range at 8 hours1

The app's half-life of about 1 hour sits within the study's range of 0.7 to 1.4 hours, and its time to peak of about 1 hour is below the study's mean of 1.5 hours, with individual peaks from 1 to 2.5 hours.1 The authors write that oral taurine "was absorbed from the gastrointestinal tract 1–2.5 hr following administration and then eliminated from plasma by first order kinetics".1 The study also notes that "Taurine is a major urinary amino acid in humans because the capacity of renal uptake is low".1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily (4 g, 12 weeks in the psychosis trial)3.

An illustration from a pharmacokinetic model using a half-life of 1 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Ghandforoush-Sattari and colleagues, Journal of Amino Acids 20101Single-dose pharmacokinetic study, noncompartmental analysis18 healthy men, median age 27.5, range 22 to 4514 g by mouth once, fasting; blood sampled to 48 hours1Half-life 1.0 ± 0.3 hours, maximum concentration at 1.5 ± 0.6 hours; no significant change in blood pressure or pulse and no complaints from volunteers1
Sun and colleagues, Hypertension 20164Randomised, double-blind, placebo-controlled4120 people with prehypertension4Taurine 1.6 g per day or placebo for 12 weeks4Mean clinic systolic BP reduction 7.2 (taurine) against 2.6 (placebo) mm Hg and diastolic 4.7 against 1.3 mm Hg; ambulatory systolic 3.8 against 0.3 mm Hg4
O'Donnell and colleagues, Journal of Clinical Psychiatry 20163Phase 2, randomised, double-blind, placebo-controlled; registered as NCT004208233,5121 patients with first-episode psychosis, aged 18 to 25 years, on low-dose antipsychotic medication; 86 analysed (47 taurine, 39 placebo)3Taurine 4 g once daily or placebo for 12 weeks3BPRS total score improved with taurine against placebo (95% CI 1.8 to 8.5; P = .004); no group difference in composite cognitive score (95% CI -1.7 to 1.0; P = .582)3
Waldron and colleagues, Sports Medicine 20186Meta-analysis of 10 articles; 7 time-to-exhaustion trials in a sub-analysis6A range of subjects in studies of isolated oral taurine; the PubMed record gives no total n61 to 6 g/day, single doses and up to 2 weeks6Overall endurance performance Hedges' g = 0.40 (95% CI 0.12 to 0.67, P = 0.004); no difference between acute and chronic supplementation (P = 0.897); dose did not moderate the effect6
Marcangeli and colleagues, Aging Cell 20257Observational, secondary analysis of a larger project; no supplement given7137 physically inactive and physically active men aged 20 to 937Blood taurine measured once, after an overnight fast7No association between circulating taurine and age, muscle mass, strength, physical performance or mitochondrial function; a significant negative correlation with performance at the step test7

Deeper analysis: Ghandforoush-Sattari and colleagues, pharmacokinetics, 2010

Each volunteer took four 1000 mg capsules, made by Life Extension Foundation Buyers Club, in the fasting morning state, with blood drawn at 0, 0.5, 1 hour and further times to 48 hours.1 The measured outcomes were plasma concentration, time of maximum concentration, area under the curve, half-life, volume of distribution and the ratio of clearance to bioavailability.1 Baseline plasma taurine ranged from 0.03 to 0.06 mmol, and the concentration returned to that range by 8 hours.1 The authors note that two volunteers, whose absorption phases took 2 and 2.5 hours, "may not have taken the drug with an empty stomach".1 The study had eight men and one dose level, so it says nothing about women, older adults, repeated dosing or the 1 to 3 g/day range the app lists.1 The authors close that "Further studies are necessary to elucidate the optimum dose of oral taurine for protecting cells against toxic agents in human".1 The acknowledgments thank laboratory staff and the volunteers and name no funder.1

Deeper analysis: Sun and colleagues, prehypertension trial, 2016

Sun and colleagues, from the Department of Hypertension and Endocrinology at Daping Hospital, Third Military Medical University, Chongqing, randomised 120 prehypertensive individuals to taurine 1.6 g per day or placebo for 12 weeks.4 The authors write that "no rigorous clinical trial has validated whether this beneficial effect of taurine occurs in human hypertension or prehypertension".4 Clinic blood pressure fell by 7.2 mm Hg systolic and 4.7 mm Hg diastolic on taurine against 2.6 and 1.3 on placebo, and ambulatory pressure fell by 3.8 mm Hg systolic and 3.5 mm Hg diastolic against 0.3 and 0.6 on placebo.4 The authors state that the effect was "especially in those with high-normal BP", and that taurine "increased plasma H2S and taurine concentrations" and improved endothelium-dependent and endothelium-independent vasodilation.4 The PubMed record for this trial gives no adverse event counts, no discontinuation numbers, no confidence intervals or P values for these differences, no funding statement and no list of the authors' limitations, so those details are not reported here; its publication-type tags include "Research Support, Non-U.S. Gov't".4 The participants were prehypertensive, and the record reports no result for people with normal blood pressure or established hypertension.4

Deeper analysis: O'Donnell and colleagues, first-episode psychosis, 2016

O'Donnell and colleagues, from Orygen, the National Centre of Excellence in Youth Mental Health in Parkville, Victoria, report a randomised, double-blind, placebo-controlled trial of adjunctive taurine, conducted from January 2007 to May 2009.3 The registry entry lists Melbourne Health as lead sponsor, with the Stanley Medical Research Institute and Southern Health as collaborators, and places the trial at ORYGEN Youth Health, a sub program of Melbourne Health, and RAPPS, a subprogram of Southern Health.5 The registry's title planned "128 Patients With First-episode Psychosis".5 The two coprimary outcomes were the Brief Psychiatric Rating Scale total score and the MATRICS Consensus Cognitive Battery composite score at 12 weeks.3 Of 121 participants, 86 (47 on taurine, 39 on placebo) were in the final analysis.3 Taurine improved the BPRS total score (95% CI 1.8 to 8.5; P = .004) and the psychotic subscale (95% CI 0.1 to 1.5; P = .026), with differences also reported on the Calgary Depression Scale (P = .047) and Global Assessment of Functioning (P = .04).3 The cognition outcome showed "no group difference in composite cognitive score (95% CI, -1.7 to 1.0; P = .582)".3 On safety and tolerability, one item of the Udvalg for Kliniske Undersogelser scale (asthenia, lassitude, increased fatigability) differed, with the taurine group showing "a more favorable outcome (P = .006)".3 The authors conclude that "Adjunctive taurine did not improve cognition, but it appears to improve psychopathology" and that "The use of taurine warrants further investigation in larger randomized studies".3 The record gives no reasons for the 35 participants outside the final analysis, no author-sponsor ties, no conflict-of-interest statement and no list of limitations, and the registry entry shows no posted results.3,5

Deeper analysis: Waldron and colleagues, endurance meta-analysis, 2018

Waldron and colleagues, from St Mary's University, London, searched databases in September 2017 and included 10 peer-reviewed articles.6 The pooled effect on overall endurance performance was Hedges' g 0.40 (95% CI 0.12 to 0.67, P = 0.004), and 0.43 (95% CI 0.12 to 0.75, P = 0.007) in the seven time-to-exhaustion trials.6 The authors report that the dose of taurine "did not moderate its effect on endurance performance", and that acute and chronic supplementation did not differ (P = 0.897).6 The authors conclude that "Human endurance performance can be improved by orally ingesting a single dose of taurine in varying amounts (1-6 g)".6 The PubMed record gives no total number of participants, no funding statement, no adverse event data and no list of limitations, and the pooled studies covered "a range of subjects" with supplementation of up to 2 weeks.6

Deeper analysis: Singh and colleagues, aging paper, Science 2023

Singh and colleagues reported in Science in 2023 that concentrations of circulating taurine "decline with aging in mice, monkeys, and humans", with authors at the Metabolic Research Laboratories, National Institute of Immunology, New Delhi and at Columbia University, New York.2 In C57Bl/6J mice, serum taurine fell from 132.3±14.2 ng/mL at 4 weeks to 40.2±7.1 ng/mL at 56 weeks, and the authors report that taurine "concentrations in elderly humans were decreased by more than 80%".2 Mice aged 14 months received taurine 1000 mg/kg body weight once daily until the end of life, and "The median lifespan increase was 10 to 12%, and life expectancy at 28 months increased by 18 to 25%".2 Aged rhesus monkeys fed taurine 250 mg/kg once daily for 6 months "gained 0.75 kg less body weight", with fasting blood glucose reduced by 19%; the paper's main text gives no group size for the monkey experiment.2 The human data in the paper were associations: in 11,966 EPIC-Norfolk participants higher taurine and hypotaurine levels went with lower body mass index, and the authors write "Association does not establish causation".2 The authors also write that "taurine supplementation in subjects with metabolic abnormalities does not affect BMI".2 After a graded cycle test, taurine levels rose 1.16-fold in all athlete groups, and the change in sedentary people was not significant (p = 0.067).2 The stated limitation is "that we have not tested the effect of taurine in male monkeys, and our association studies in humans did not distinguish between sexes", and the authors close that "Clinical trials in humans seem warranted".2 Funding included an NIH grant (R01HD107574) and a Nathan Shock Center project grant, and the competing-interests statement reads "Columbia University has filed provisional patent applications for which VKY is an inventor".2

Deeper analysis: Marcangeli and colleagues, human test of the aging hypothesis, 2025

Marcangeli and colleagues, writing in Aging Cell in 2025, tested the taurine-deficiency hypothesis in 137 men aged 20 to 93, requiring men aged 20 to 100 with a body mass index of 18 to 35 kg/m2.7 They report "No association between circulating taurine levels and age, muscle mass, strength, physical performance, or mitochondrial function".7 They conclude that taurine deficiency "is therefore unlikely to be a primary driver of aging in humans".7 The authors also note that the study "does not rule out potential positive health impacts of taurine supplementation in older adults, especially in individuals with low circulating taurine levels and individuals with chronic diseases".7 The study was a secondary analysis of men only, measured blood taurine rather than giving a supplement, and so tests the association in the 2023 paper and not the effect of supplementation.7 Funding came from the Canadian Institutes of Health Research and other Canadian bodies, and the authors "declare no conflicts of interest".7 The two papers differ on the human question, and no human supplementation trial on aging outcomes was identified in the PubMed records returned.2,7

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels8 rows
SourceDose and routeWho or whatLength
App, typical range1 to 3 g/day, oralThe app's figurePer day
Ghandforoush-Sattari 201014 g by mouth, fasting8 healthy menSingle dose
Sun 201641.6 g per day120 people with prehypertension, against placebo12 weeks
O'Donnell 201634 g once daily, against placebo121 people with first-episode psychosis on low-dose antipsychotic medication12 weeks
Waldron 201861 to 6 g/dayPooled studies of isolated oral taurine in a range of subjectsSingle doses and up to 2 weeks
Singh 2023, mice (animal)21000 mg/kg body weight once daily14-month-old miceUntil end of life
Singh 2023, rhesus monkeys (animal)2250 mg/kg body weight once dailyAged monkeys6 months
EFSA 2009, level without observed adverse effect81,000 mg per kg of body weight per dayThe no observed adverse effect level the panel confirmed for taurineNot stated in the release

In the pharmacokinetic study, the authors report that blood pressure and pulse did not change significantly and "the volunteers had no complaint during the study", in 8 men after a single 4 g dose.1 In the psychosis trial, the only safety scale difference reported in the record favoured taurine on one item, and the record lists no other adverse event counts.3 The records of the blood pressure trial and the endurance meta-analysis report no adverse events, so no rates can be given for them.4,6 The pharmacokinetic study's authors write that "With few exceptions, animal and human studies have demonstrated that taurine, even in high doses, is generally free of any serious adverse effects".1 Singh and colleagues write that taurine "has no known toxic effects in humans (though rarely used in concentrations used here)".2 EFSA noted reports of acute health problems, including fatalities, in young people consuming energy drinks either in very high amounts, with physical exercise or more frequently with alcohol, and said co-consumption of alcohol and/or drugs in most cases makes the cases particularly difficult to interpret; with regard to some recent reports it considered high caffeine intake possible, while "the assumption of a causal relationship with taurine intake is lacking scientific evidence".8

The app lists no markers to monitor for taurine. Baseline plasma taurine in the pharmacokinetic study was 0.04 ± 0.0 mmol, ranging from 0.03 to 0.06 mmol.1 The authors report urinary losses of taurine that "generally range from 65 to 250 mg (0.5–2.0 mmoL)" per day and are diet-dependent.1 The blood pressure trial measured clinic and 24-hour ambulatory blood pressure and plasma H2S and taurine concentrations.4 The 2023 aging paper measured serum taurine, hypotaurine and N-acetyltaurine in people, and in monkeys reported serum AST and ALT lower by about 36% and 20% on taurine.2

8

Regulatory and anti-doping status

EFSA's Panel on Food Additives and Nutrient Sources added to Food concluded in 2009 that "exposure to taurine and d-glucuronolactone through regular consumption of energy drinks was not of safety concern".8 The panel reported a no observed adverse effect level of 1,000 mg per kilogram of body weight per day, and judged that mean and high-level consumers drinking 125 ml and 350 ml a day had a sufficient margin of safety.8 The chair of EFSA's ANS Panel said the opinion "evaluated the safety of these two ingredients as constituents of energy drinks, rather than energy drinks themselves".8 EFSA also noted that exposure data came from 2003 and that current consumption data in adolescents and young adults "may need to be collected", and the news release carries the notice "This article was published over 10 years ago and may not reflect current information".8 The word taurine does not appear in the text of the World Anti-Doping Agency's 2026 Prohibited List that was searched.9 No product label for taurine was among the documents read, which were the EFSA news release and the WADA list.

No controlled trial of taurine in people for aging outcomes or lifespan was identified in the PubMed records returned for the queries used.2 The app's notes mention hydration, cramp prevention and sleep continuity, and none of the studies described above reports a hydration, cramp or sleep outcome. No randomised trial of oral taurine for sleep in people was identified in the PubMed records returned for "taurine sleep GABA". No study of absolute oral bioavailability of taurine was identified in the PubMed records returned, so no study figure sits beside the app's 80%. The pharmacokinetic study covers a single 4 g dose in 8 men, so repeated-dose, sex-specific and food-effect pharmacokinetics at 1 to 3 g/day are not described in the cited sources.1 No study of taurine at 2 g at night, the figure named in the app's notes, was identified in the PubMed records returned for "taurine sleep GABA". The two aging papers disagree on whether blood taurine tracks age in people, and neither tested supplementation in people.2,7

What is taurine?

Taurine is a sulfur-containing amino acid that is a normal constituent of the human diet.1

What is the half-life of taurine?

The plasma elimination half-life of taurine was 1.0 ± 0.3 hours in a study of 8 healthy men given 4 g by mouth, and the app lists about 1 hour.1 Individual half-lives in that study ranged from 0.7 to 1.4 hours.1

How long does taurine take to reach its peak level?

Maximum plasma taurine was reached at a mean of 1.5 ± 0.6 hours (range 1 to 2.5 hours) after 4 g by mouth, while the app lists about 1 hour.1

What is the bioavailability of taurine?

The app lists 80%, and the one oral pharmacokinetic study identified reports a clearance to bioavailability ratio of 21.1 ± 7.8 L/hr and no bioavailability percentage.1

Is taurine banned by WADA?

The word taurine does not appear in the text of the WADA 2026 Prohibited List that was searched.9

Did EFSA find taurine in energy drinks safe?

EFSA's panel concluded in 2009 that exposure to taurine through regular consumption of energy drinks was not of safety concern.8 The opinion was about energy drinks, with a no observed adverse effect level of 1,000 mg per kg of body weight per day.8

Does taurine lower blood pressure?

In a 12-week trial of 120 prehypertensive people on 1.6 g per day, mean clinic systolic pressure fell by 7.2 mm Hg on taurine and 2.6 mm Hg on placebo.4

Does taurine improve endurance performance?

A meta-analysis of 10 articles reported Hedges' g of 0.40 (95% CI 0.12 to 0.67, P = 0.004) for overall endurance performance with oral taurine.6

Does taurine extend lifespan in humans?

No human trial of taurine on lifespan was identified in the PubMed records returned, and the 10 to 12% rise in median lifespan was reported in mice.2

12

References

  1. Ghandforoush-Sattari M, et al. Pharmacokinetics of oral taurine in healthy volunteers. J Amino Acids 2010. PMID 22331997
  2. Singh P, et al. Taurine deficiency as a driver of aging. Science 2023. PMID 37289866
  3. O'Donnell CP, et al. Adjunctive taurine in first-episode psychosis: a phase 2, double-blind, randomized, placebo-controlled study. J Clin Psychiatry 2016. PMID 27835719
  4. Sun Q, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension 2016. PMID 26781281
  5. Melbourne Health. A study of taurine in patients with first-episode psychosis receiving antipsychotic treatment. ClinicalTrials.gov NCT00420823. NCT00420823
  6. Waldron M, et al. The effects of an oral taurine dose and supplementation period on endurance exercise performance in humans: a meta-analysis. Sports Med 2018. PMID 29546641
  7. Marcangeli V, et al. Experimental evidence against taurine deficiency as a driver of aging in humans. Aging Cell 2025. PMID 41061678
  8. European Food Safety Authority. EFSA adopts opinion on two ingredients commonly used in some energy drinks. News release, 12 February 2009. EFSA news release
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list